Perrigo Company plc (PRGO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. Basic financial performance shows some decline in gross profit and margin, but EPS grew slightly. Product development is hindered by slower-than-expected recovery in Infant Formula. Market strategy shows potential with new SKUs, though facing execution challenges. Expenses are managed well, but tariffs are a concern. The shareholder return plan remains stable. Q&A highlights management's unclear responses on critical issues, adding uncertainty. Overall, the sentiment is neutral, with no significant catalysts or detractors to drive the stock price significantly in either direction.
Key Financial Performance
Organic net sales (Q3 2025) Declined 4.4%, impacted by 1.6% from global OTC business due to soft OTC category consumption and 2.8% from businesses under review (Oral Care and Infant Formula).
Gross profit and margin (Q3 2025) Gross profit was $417 million, down $30 million year-over-year. Gross margin declined 110 basis points due to lower net sales, divestitures, and exited products.
Operating profit and margin (Q3 2025) Operating profit was $173 million, down 4.9% year-over-year due to lower net sales flow-through and higher operating expenses in Infant Formula. Partially offset by benefits from Project Energize and cost management.
Earnings per share (EPS) (Q3 2025) $0.80, up $0.01 versus the prior year, driven by cost management and operational improvements.
Year-to-date organic net sales (2025) Declined 1.7%, driven by 0.8% from businesses under review and 0.5% from absence of last year's Opill launch stocking benefits.
Year-to-date gross and operating margins (2025) Expanded, with organic operating income growing 13% due to accretive initiatives, Infant Formula recovery, and cost management.
Year-to-date EPS (2025) Grew 21% (27% organically) to $1.97, driven by operational improvements and cost management.
Project Energize Generated $163 million in gross annual savings, above the midpoint of the $140 million to $170 million range.
Supply chain reinvention On track to deliver $150 million to $200 million in benefits by the end of 2025.
Infant Formula business (Q3 2025) Stabilized operationally, but store brand share recovery is slower than expected, contributing to a $100 million impact on net sales.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Infant Formula: Stabilized operationally but store brand share recovery is slower than expected. Strategic review announced to assess its long-term role within Perrigo's portfolio. Investment of $240 million paused.
OTC Products: Perrigo's U.S. OTC store brand gained volume share for 6 consecutive months, driven by strong execution, consumer trade from national brands, and new distribution. In Europe, key brands like ellaOne and Jungle Formula gained dollar share for 5 consecutive months.
U.S. OTC Market: Perrigo outperformed despite a challenging market, gaining 90 basis points in volume share over 13 weeks in categories like smoking cessation, allergy, and women's health.
European OTC Market: Despite a decline in total OTC euro consumption, Perrigo's key brands gained dollar share for 5 consecutive months, driven by focused A&P investments and targeted activation strategies.
Supply Chain Reinvention: On track to deliver $150 million to $200 million in benefits by the end of 2025.
Project Energize: Generated $163 million in gross annual savings, exceeding the midpoint of the $140 million to $170 million range.
Portfolio Streamlining: Sale of Dermacosmetics business on track to close in Q1 2026. Strategic reviews of Infant Formula and Oral Care businesses are ongoing.
Leadership and Innovation: New leadership team in place, scaling brand-building capabilities, and implementing a commercial growth model to enhance efficiency and market reach.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Soft OTC category consumption trends: Both U.S. and European OTC markets are experiencing softer-than-expected consumption trends, leading to a decline in net sales and impacting financial performance.
Infant Formula business challenges: The recovery of store brand share in the Infant Formula segment is slower than anticipated, compounded by the loss of Good Start brand distribution. This has resulted in a $100 million impact on the 2025 net sales outlook.
Strategic review of Infant Formula and Oral Care businesses: The company is conducting strategic reviews of these businesses, which may require sustained investment and management focus, potentially diverting resources from core operations.
Supply chain reinvention and cost management pressures: While the supply chain reinvention project is on track, achieving the targeted $150-$200 million in benefits requires continued focus and execution, posing operational risks.
Market consumption unpredictability: Year-to-date consumption trends in consumer health have been dynamic and unpredictable, with significant declines in the third quarter, creating challenges in forecasting and planning.
Gross margin pressures: Gross margins have declined due to lower net sales, divestitures, and a shift towards lower-margin store brands, impacting profitability.
Leverage and debt management: Updated financial outlook projects a higher year-end net debt to adjusted EBITDA ratio of 3.8x, above the prior target of 3.5x, due to revised net sales expectations.
Paused investment in Infant Formula: The previously announced $240 million investment in the Infant Formula business has been paused, reflecting uncertainties in its long-term strategic fit and external market conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Organic Net Sales Outlook: Revised to a decline of 2% to 2.5% due to softer-than-expected OTC category consumption in both the U.S. and Europe, as well as lower-than-anticipated Infant Formula share growth.
Gross Margin for 2025: Expected to be approximately 39% for the year.
Operating Margin for 2025: Reaffirmed at approximately 15% for the year, supported by benefits from accretive initiatives and prudent cost management.
2025 Earnings Per Share (EPS) Outlook: Updated to a range of $2.70 to $2.80, representing 5% to 9% growth versus 2024.
Infant Formula Business Strategic Review: The company is assessing the long-term role of the Infant Formula business within its portfolio, considering a full range of options and pausing the previously announced $240 million investment.
Dermacosmetics Divestiture: On track to close in the first quarter of 2026, with proceeds expected to support deleveraging goals.
Oral Care Business Strategic Review: The strategic review of the Oral Care business is ongoing.
Q4 2025 Organic Growth Expectations: Global OTC business expected to grow approximately flat to 1%, while Nutrition category sales are expected to decline year-over-year due to lower contract volumes and prior year restocking activity.
Q4 2025 Margins: Expected to be below prior year levels due to lower volumes and tariff-related costs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Sustainability: The company remains committed to sustaining its dividend as part of its corporate priorities.
Dividend Returns: Year-to-date, Perrigo has returned $119 million to shareholders through dividends.
Share Repurchase Program: No mention of a share repurchase program was made during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What caused the wide spread between sell-out data and sell-in for Infant Formula, and how are the new SKUs performing?
A:The wide spread was mainly due to retailer destocking and competitive pressure from imported formulas. The new SKUs have built distribution as planned, but their velocity is below expectations due to shelf positioning and space allocation issues.
Q:What were the supply constraints in Women's Health, and what is driving the deprioritization of nutraceuticals in VMS?
A:Supply constraints in Women's Health were related to the L1 brand in Europe, which have now been resolved. The deprioritization of nutraceuticals in VMS is due to a focus on better-performing brands in the Netherlands and Germany. Additionally, soft OTC consumption and weaker international VMS consumption were noted.
Q:What changed intra-quarter for OTC and Infant Formula, and what is driving the volatile consumption in staples?
A:OTC consumption slowed from Q2 onwards, with a decline in August and October. Infant Formula velocities were below expectations, affecting revenue and share growth. Volatile consumption is attributed to tactical factors like pricing, distribution, and display levels, but no structural changes were identified.
Q:What are the company's reinvestment plans given the pullback in OTC consumption and paused Infant Formula investment?
A:The company plans to revisit capital allocation, focusing on organic growth in performing businesses like U.S. store brands and international branded businesses. Priorities remain deleveraging and maintaining dividends, with potential increased allocations for growth opportunities.
Q:What is the current Infant Formula market share, and what are the expectations for 2026?
A:The current Infant Formula market share is about 16%, with expectations to grow to 18%-20% over the next 12 months. The company is conducting a strategic review to optimize the business for near- and long-term shareholder value.
Q:What are the expectations for EBITDA growth in 2026, and what are the headwinds and tailwinds?
A:The company expects stabilization in the OTC market and share gains slightly ahead of the market. Headwinds include foreign manufacturers' U.S. share growth, idle domestic capacity, and the Dermacosmetics divestiture. Tailwinds include a stronger innovation pipeline, improved brand programs, and expanded market rollouts.
Q:What caused the 110 basis points of gross margin pressure in the quarter, and how will tariffs impact margins?
A:The gross margin pressure was due to sales deleverage and mix, not input costs or competitive price changes. Tariffs are expected to impact margins by $40-$50 million, mitigated by pricing and manufacturing actions, with no lag expected in cost recovery.
Q:Will tariffs and sourcing changes affect market share in 2026?
A:The company expects its strong U.S. manufacturing position to drive share gains and strategic partnerships with retailers, despite dynamic scenarios like China tariffs.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following: 1) Specific actions to address the slower-than-expected velocity of new SKUs in Infant Formula. 2) Detailed data or evidence supporting the hypothesis of consumers burning through pantry stock. 3) Exact plans for reallocating investments following the strategic review of the Infant Formula business.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AP investment
Dermacosmetics divestiture
EU
OTC category
OTC consumption
OTC market
OTC portfolio
OTC volume
Opill launch
Oral Care
absence Opill
addition brand
benefit OTC
benefit supply
brand distribution
brand ellaOne
brand share
business review
category Europe
category consumption
category contract
chain reinvention
challenge date
consumer health
consumption Europe
consumption store
consumption trend
environment
gain Europe
health sale
marketplace challenge
point OTC
priority
resilience
review Oral
sale OTC
share month
strength
value proposition
PRGO Transcript
Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary indicates a positive sentiment with a 5% revenue increase, 10% rise in adjusted operating income, and improved gross margin. Despite risks associated with regulatory hurdles and strategic execution, these financial metrics and operational efficiencies suggest a favorable outlook. The lack of negative sentiment in the Q&A and the strong demand in the consumer health segment further support a positive stock price movement prediction over the next two weeks.
Perrigo Company plc (PRGO) Presents at UBS Global Consumer and Retail Conference Transcript
Neutral3-11
Perrigo Company plc (PRGO) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture: strong EPS growth and operational improvements are offset by declining sales and margins. The Q&A reveals management's optimism for 2026 and beyond, but uncertainties around specific business segments persist. The strategic reviews and divestitures indicate potential future improvements, but immediate impacts are unclear. Overall, the sentiment is balanced, suggesting a neutral stock price movement in the short term.
Perrigo Company plc (PRGO) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals mixed signals. Basic financial performance shows some decline in gross profit and margin, but EPS grew slightly. Product development is hindered by slower-than-expected recovery in Infant Formula. Market strategy shows potential with new SKUs, though facing execution challenges. Expenses are managed well, but tariffs are a concern. The shareholder return plan remains stable. Q&A highlights management's unclear responses on critical issues, adding uncertainty. Overall, the sentiment is neutral, with no significant catalysts or detractors to drive the stock price significantly in either direction.
PRGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
